NS-229

Phase 2Small molecule

NS Pharma

NS-229 is one of 21 small molecule programs targeting Granulomatosis with Polyangiitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Granulomatosis With PolyangiitisActive, not recruiting

Granulomatosis With PolyangiitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Granulomatosis With Polyangiitis

#DrugCompanyPhaseTrials

Rayos

Orencia

1 3

Actemra

Roche

Phase 3

1 4

Nucala

GGlaxo Dba Glaxosmithkline

Phase 3

3 5

Tavneos

Amgen

Phase 3

1 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 7

Imuran

LLegacy Health System

Phase 3

1 8

Xeljanz

PPrism Pharmaceuticals

Phase 3

1 9

EXDENSUR

GGlaxo Dba Glaxosmithkline

Gazyva

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Granulomatosis with Polyangiitis1 trial

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Recruiting· NS Pharma logo

NS Pharma·Phase 2·NCT06046222·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NS-229. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NS-229 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NS-229. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NS Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NS Pharma

NS-229

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Granulomatosis with Polyangiitis1 trial

References

Drug Info

Quick Facts

Related News